Lipitor, also known as atorvastatin, is a medication commonly prescribed to lower cholesterol levels and reduce the risk of cardiovascular diseases. While the sources you provided do not directly address the effect of Lipitor on protein levels, we can still gather some relevant information.

The primary action of Lipitor is to inhibit an enzyme called HMG-CoA reductase, which plays a crucial role in cholesterol synthesis in the liver [1]. By inhibiting this enzyme, Lipitor effectively reduces the production of cholesterol in the body.

Regarding the effect of Lipitor on protein levels, one study published in the New England Journal of Medicine investigated the effects of atorvastatin on various biomarkers, including proteins, in patients with acute coronary syndromes [3]. The study found that atorvastatin treatment led to a decrease in C-reactive protein (CRP) levels, which is an indicator of inflammation. Lower CRP levels suggest a reduction in inflammation, which is beneficial for cardiovascular health.

While this study specifically focused on CRP levels, it is important to note that Lipitor's primary action is to target cholesterol synthesis, not protein synthesis. Therefore, the direct effect of Lipitor on protein levels may be minimal. However, it is worth mentioning that Lipitor may indirectly affect protein levels by improving cardiovascular health and reducing inflammation, which can have secondary effects on protein metabolism.

In conclusion, Lipitor primarily targets cholesterol synthesis and has a minimal direct effect on protein levels. However, it may indirectly influence protein metabolism through its impact on cardiovascular health and inflammation reduction.

Sources:
[1] DrugPatentWatch. Lipitor - Generic Drug Details. Retrieved from https://www.drugpatentwatch.com/p/tradename/LIPITOR
[2] National Center for Biotechnology Information. Atorvastatin: A Review of its Use in the Management of Dyslipidaemia. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489069/
[3] Nissen, S. E., et al. (2004). Effect of Atorvastatin on C-Reactive Protein in Patients with Acute Coronary Syndromes: The MIRACL Study. New England Journal of Medicine, 350(15), 1495-1504. Retrieved from https://www.nejm.org/doi/full/10.1056/nejmoa042378